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ABSTRACT
Objectives: To examine the long-term efficacy at the
36-month follow-up of an early psychosocial
counselling and support programme lasting
8–12 months for community-dwelling patients with
mild Alzheimer’s disease and their caregivers.
Design: Multicentre, randomised, controlled, rater-
blinded trial.
Setting: Primary care and memory clinics in five
Danish districts.
Participants: 330 home-dwelling patients with mild
Alzheimer’s disease and their primary caregivers
(dyads).
Interventions: Dyads were randomised to receive
intervention during the first year after diagnosis. Both
intervention and control groups had follow-up visits at
3, 6, 12 and 36 months.
Main outcome measures: Primary outcomes for the
patients assessed at 36-month follow-up were changes
from baseline in global cognitive function (Mini-Mental
State Examination), depressive symptoms (Cornell
Depression Scale) and proxy-rated EuroQoL quality of
life on visual analogue scale. The primary outcomes
for the caregivers were changes from baseline in
depressive symptoms (Geriatric Depression Scale) and
self-rated EuroQoL quality of life on a visual analogue
scale. The secondary outcome measures for the patient
were proxy-rated Quality of Life Scale for Alzheimer’s
disease (QoL-AD), Neuropsychiatric Inventory-
Questionnaire, Alzheimer’s disease Cooperative Study
Activities of Daily Living Scale, all-cause mortality and
nursing home placement.
Results: At a 36-month follow-up, 2 years after the
completion of the Danish Alzheimer Intervention Study
(DAISY), the unadjusted positive effects previously
detected at the 12-month follow-up in one patient
primary outcome (Cornell depression score) and one
patient secondary outcome (proxy-rated QoL-AD)
disappeared (Cornell depression score, p=0.93; proxy-
rated QoL-AD, p=0.81). No long-term effect of DAISY
intervention on any other primary and secondary
outcomes was found at the 36-month follow-up.
Conclusions: For patients with very mild Alzheimer’s
disease and their caregivers, an intensive, multi-
component, semitailored psychosocial intervention
programme with counselling, education and support
during the first year after diagnosis did not show any
positive long-term effect on primary and secondary
outcomes.
Strengths and limitations of this study
▪ This is the largest randomised controlled trial of
early psychosocial intervention for patients with
mild Alzheimer’ disease and their caregivers to
date, with a long follow-up of 3 years.
▪ It is a study of solid methodology, strictly adher-
ing to CONSORT recommendations.
▪ The multicomponent semitailored intervention
programme was intensive in both content and
duration, targeted multiple needs, tended to the
individual needs and simultaneously involved
caregivers and patients; thus, having the charac-
teristics that defined successful intervention pro-
grammes documented in the literature.
▪ Multiple primary and secondary outcomes were
chosen based on the specific aims of DAISY and
on the outcomes from similar intervention
studies for patients with more advanced demen-
tia. To avoid finding spurious effects, a conser-
vative significance level was set at p=0.0005.
▪ All patients had primary caregivers who are very
much involved in caregiving, a situation that
cannot be generalised to all patients with demen-
tia in Denmark.
▪ There was assessment of need at baseline.
▪ Intervention lasted 1 year but without continuous
follow-up and support during the subsequent
2 years.
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Trial registration: The study was registered in the Clinical Trial
Database (http://www.controlled-trials.com/ISRCTN74848736).
INTRODUCTION
Psychosocial interventions for patients with Alzheimer’s
disease (AD) and their caregivers have gained recogni-
tion during the past two decades. The majority of
patients with dementia live in their own homes with
their caregivers, usually their spouses, who bear the
responsibility of caregiving.1 Caring for family members
with dementia has long been considered as the most
stressful type of family caregiving, predisposing care-
givers to mental and physical illnesses and increasing
their risk for death.2 Previously an under-researched
area, the needs of patients with AD have received more
attention in recent years, with studies documenting their
need for information about their illness, for help to
cope with their disabilities, for social recognition and
support and for a decent quality of life with meaningful
social contact and activities.3 Patients’ unmet needs can
result in mood and behavioural problems, safety issues,
social isolation and increased risk for nursing home
placement and death.4 Meta-analyses and systematic
reviews of the numerous clinical trials assessing the efﬁ-
cacy of psychosocial interventions for caregivers have
shown a signiﬁcant effect of interventions on reducing
caregivers’ psychological morbidity and reduce patients’
neuropsychiatric symptoms.5–9 Studies examining the
effect of psychosocial intervention on patients’ mortality
and nursing home placement are scarce and the results
are inconsistent.5 10 Studies that included psychosocial
interventions for the patients are limited, providing
anecdotal evidence for positive effects of interventions
on patients’ cognitive function, psychological morbidity
and time to nursing home placement.10 Today, thanks to
the remarkable advances in diagnosing dementia,
patients can be diagnosed at an early stage when their
relatively intact autonomy and insight enable them to
convey their needs and actively participate in interven-
tion programmes. The rapidly growing number of
people with AD in the coming years, a considerable pro-
portion of them diagnosed in the early stages, presents a
pressing need to develop and validate intervention pro-
grammes that focus on the needs of patients with mild
dementia and their caregivers and involve both parties
in the intervention.
It was hypothesised that the Danish Alzheimer
Intervention Study (DAISY), a multifaceted and semitai-
lored intervention programme offered to patients with
AD and their primary caregivers during the ﬁrst year
after the diagnosis, could have a long-term effect in pre-
venting the emergence of depressive symptoms, improv-
ing quality of life for the patients and the caregivers,
stabilising the patients’ cognitive function and delaying
nursing home placement.1 The results of the 12-month
follow-up were published in BMJ in 2012, showing no sig-
niﬁcant difference in outcomes between the DAISY and
the control groups.11 However, the signiﬁcant level cor-
rected for multiple testing (p=0.0005) was subsequently
criticised for being too conservative, given that an alter-
native correction method could have given another con-
clusion.12 Before adjustment for multiple testing was
carried out, the data analysis of the results at the
12-month follow-up had shown statistical signiﬁcance in
one primary patient outcome (Cornell Depression Scale
score, p=0.0103) and one secondary patient outcome
(proxy-rated quality of life QoL-AD, p=0.0013) in favour
of the DAISY group.11 Therefore, a 36-month follow-up
was subsequently carried out to follow the evolution of
these outcomes. This paper reports the results of this
follow-up.
METHODS
Detailed description of the study rationale, methods,
design, randomisation and sample size has been
published.1
Trial design
DAISY was a large multicentre, rater-blinded, 1-year ran-
domised controlled trial of the efﬁcacy of intensive psy-
chosocial intervention for patients with mild AD and
their caregivers. It was an exploratory randomised clin-
ical trial with multiple primary and secondary outcomes.
Participants
The patients were recruited from ﬁve Danish districts.
One designated memory clinic in each district recruited
the patients for the trial. Each recruiting centre had one
study co-ordinator and one physician who assessed the
patients for eligibility. Patients were referred from local
memory clinics as well as private practice in psychiatry,
neurology, geriatrics and family medicine. If referred
from private practice, dementia diagnosis was conﬁrmed
by specialists in the recruiting memory clinic.
The inclusion criteria were (1) home-living patients
diagnosed within the past 12 months with AD, mixed
AD with vascular component or Lewy body dementia;
(2) 50 years of age or older; (3) Mini-Mental State
Examination (MMSE) score ≥2013 and (4) having one
participating primary caregiver. The primary caregiver
was deﬁned as the main person responsible for the
informal care of the patient with minimum weekly
contact. All patients met DSM-IV criteria for dementia,14
NINCDS-ADRDA criteria for probable AD15 or McKeith
criteria for Lewy body dementia.16 Patients with mixed
AD were those with probable AD and minor vascular
changes on cranial CT that could contribute to their
symptoms.
Patients with severe somatic or psychiatric comorbid-
ities (including impaired hearing or vision) that would
signiﬁcantly impair their compliance with the DAISY
programme were excluded. Patients who had already
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been involved in other intervention programmes were
also excluded. Patient–caregiver dyads were randomised
to the DAISY group, in which they were provided with
intensive psychosocial interventions and follow-up
support at 3, 6 and 12 months; or to the control group,
in which they were only provided with follow-up support
at 3, 6 and 12 months. The study was subsequently
extended and the patients and their caregivers were
asked to give a separate consent to an additional
follow-up at 36 months.
Intervention
A multifaceted and semitailored psychosocial interven-
tion programme described in details in our previous
reports1 11 was designed to provide counselling, informa-
tion and support to patients with mild dementia and
their caregivers in the intervention group. The study
co-ordinator in each centre, an experienced nurse spe-
cialising in caring for patients with dementia and having
received special training in counselling for the study
(constructivist approach),17 implemented the interven-
tion within the ﬁrst month after inclusion in the trial.
Consisting of ﬁve key components, the intervention
focused on positive resources, intact function, retained
skills and feasible activities for the patients: (1) the study
co-ordinator provided seven individual counselling ses-
sions tailored to the needs of the patients and their care-
givers: two for the patient alone, two for the caregiver
alone, two for the patient–caregiver dyad and one with
the dyad together with their family network (optional);
(2) the study co-ordinator provided outreach telephone
counselling 5–8 times with 3–4 week intervals to main-
tain regular contact and follow-up on the individual
counselling sessions; (3) using log books, the patients
and their caregivers independently kept track of the
thoughts and daily issues that they wanted to discuss at
the counselling sessions; (4) experts in the ﬁeld of
dementia were invited to teach ﬁve standard courses as
group intervention with separate courses for patients
and caregivers to provide general information about
dementia and forum for discussion, sharing information
and support and (5) patients and caregivers were pro-
vided with information folders produced especially for
the purpose of the study about dementia causes, diagno-
sis and treatment, legal issues and resources for social
support. The intervention programme lasted 8–12
months. Full compliance was deﬁned as adherence with
the major components of the intervention programme:
patients who participated with their caregivers in at least
three counselling sessions (not including the optional
network session) and in at least three teaching course
sessions.
The patients in both the intervention and the control
groups were followed up at 3, 6, 12 and 36 months.
Attempts were made to provide similar treatment for
both intervention and control participants in all respects
other than the add-on DAISY. At each follow-up visit,
participants in both groups were interviewed about their
current symptoms and daily-life issues, and informed
about available support programme (if any) in their
local communities. Both groups were free to participate
in such support programmes during the study and par-
ticipation in these support activities was registered for
both groups. Identiﬁed special needs led to referral to
local care facilities when available and relevant.
Outcomes
Primary outcomes for the patients
1. Global cognitive function: The patient’s global cogni-
tive function was assessed using MMSE.13 The sum of
scores ranges from 0 to 30. Higher scores indicate
better cognitive function.
2. Depressive symptoms: Cornell Scale for Depression in
Dementia was used to assess the patient’s depressive
symptoms through an interview with both the patient
and caregiver.18 The scale has 19 items, each item
rating a speciﬁc depressive symptom in increasing
severity (0–2), yielding a total score ranging from 0
to 38, with higher scores indicating more depressive
symptoms. A score ≥8 indicates signiﬁcant depressive
symptoms and a score ≥10 indicates major
depression.
3. Proxy-rated quality of life: The primary caregiver eval-
uated the patient’s health-related quality of life using
the EuroQoL EQ-5D,19 a questionnaire inquiring
about mobility, self-care, activities, pain, discomfort,
anxiety and depression. Quality of life was rated using
a visual analogue scale (EQ-VAS) with scores ranging
from 0 to 100. Higher scores signify better quality
of life.
Primary outcomes for the primary caregivers
1. Depressive symptoms: The caregivers rated their own
depressive symptoms using the Geriatric Depression
Scale.20 The total score ranges from 0 to 30 with
higher score indicating more depressive symptoms. A
cut-off score of 10 distinguishes between depressed
and non-depressed individuals.
2. Self-rated quality of life: The caregivers rated their
own health-related quality of life using the EQ-VAS.19
The scores range from 0 to 100 with higher scores
indicating good quality of life.
Secondary outcomes for the patients
1. Proxy-rated quality of life, AD-speciﬁc: The caregiver
rated the patient’s quality of life using Quality of Life
Scale for Alzheimer’s Disease (QoL-AD),21 a 13-item
scale measuring disease-speciﬁc quality of life in
people with AD. Total score ranges from 13 to 52
with higher scores indicating better quality of life.
2. Neuropsychiatric symptoms: The patient’s neuro-
psychiatric and behavioural symptoms were assessed
through an interview with the caregiver using
Neuropsychiatric Inventory-Questionnaire.22 Total
score ranges from 0 to 36 with higher scores indicat-
ing more severe disturbances.
Phung KTT, Waldorff FB, Buss DV, et al. BMJ Open 2013;3:e003584. doi:10.1136/bmjopen-2013-003584 3
Open Access
3. Activities of daily living: The caregiver completed the
Alzheimer’s Disease Cooperative Study Activities of
Daily Living Scales for clinical trials in Alzheimer’s
disease (ADCS-ADL)23 to assess the patient’s activities
of daily living. ADCS-ADL is a 23-item scale with total
scores ranging from 0 to 78. Higher scores indicate
better functioning.
4. Mortality and nursing home placement: The Danish
Civil Registration System24 was used together with
personal contact with the caregivers to collect infor-
mation regarding death and nursing home place-
ment. In case of doubt, the local district authority or
the residential place was contacted to check whether
the address was registered as a nursing home.
BASELINE AND FOLLOW-UP ASSESSMENTS
Both patients and their caregivers were invited to partici-
pate in all the assessments. The local study coordinator
carried out the baseline assessment prior to randomisa-
tion at the local study centre. Independent raters blind
to group assignment carried out follow-up assessments at
6, 12 and 36 months during home visits. The raters were
neither involved in the intervention programme nor
employed in the same institutions as the study
co-ordinators. The efﬁciency of concealment was
checked through questionnaires administered to the
raters at the end of each follow-up visit. None of the
raters visited the same patient–caregiver dyad more than
once.
Statistical methods
Characteristics and outcome measures at baseline of the
dyads in the intervention and control groups were com-
pared using Student t tests for continuous variables and
χ2 tests for categorical variables. With linear models on
the full data of up to four observations per dyad, we
compared the difference in development of the primary
and secondary outcomes between randomisation groups
during the follow-up period, using generalised estimat-
ing equations to account for repeated measurements;
the inclusion of a categorical centre indicator variable
account for possible clustering by treating centre. To
adjust for possible bias because of differential death and
dropout from the study between the intervention and
control groups, the assessments at the various follow-up
times were weighted by the inverse of an estimate of the
probability of staying in the study, a method explained
in the seminal paper by Dufouil et al25 These probabil-
ities were estimated from the data in logistic regression
models for death and dropout with the dyads’ character-
istics and the observed primary outcomes from previous
visits as covariates. Only the expected scores and infer-
ences for the 36-month follow-up were reported.
Differences in mortality and nursing home placement
rates between the two groups were evaluated by HR
from a Cox regression model. All analyses were carried
out using the intention-to-treat principle.
RESULTS
Five hundred and ﬁfty-eight patients were screened for
eligibility and 330 patient–caregiver dyads were
included: 163 were randomised to DAISY group and 167
to control group (ﬁgure 1). Their demographics, clin-
ical characteristics and outcome measures at baseline
are provided in table 1. Most patients received
cognition-enhancing medications (93.3% cholinesterase
inhibitor and 1% NMDA receptor antagonist).1 Overall,
the participation rate in the DAISY group was high.11
At 36 months, a total of 130 patients (67 in the inter-
vention group and 63 in the control group) were lost for
follow-up (ﬁgure 1). In all, 56 patients had deceased, 36
from the DAISY group and 20 from the control group
(ﬁgure 1). Patients in the DAISY had a higher mortality
rate (HR 1.99; 95% CI 1.15 to 3.43; p=0.01). Regarding
nursing home placement, 43 patients from DAISY group
and 48 from the control group were placed in nursing
homes at the 36-month follow-up. Data on nursing home
placement was missing for ﬁve participants in the inter-
vention group. There was no difference between the rates
of nursing home placement for the intervention and
control groups (HR 0.97; 95% CI 0.64 to 1.47; p=0.89).
As reported previously, the 12-month follow-up study
observed positive effects of DAISY on preventing the
emergence of depressive symptoms (Cornell depression
scale, primary patient outcome) and maintaining quality
of life (proxy-rated QoL-AD, secondary patient
outcome).11 The effect size of DAISY regarding Cornell
depression score was –1.58 (–2.79 to –0.37, p=0.0103)
and regarding proxy-rated QoL-AD was 2.14 (0.83 to
3.45; p=0.0013). In this 36-month follow-up study, which
took place after DAISY had stopped for 2 years, there
was no signiﬁcant difference between intervention and
control groups regarding these two outcomes (Cornell
depression score, p=0.93; proxy-rated QoL-AD, p=0.82;
tables 2 and 3). The effect size of DAISY regarding
Cornell depression score was –0.06 (−1.43 to 1.32;
p=0.93) and regarding proxy-rated QoL-AD was –0.19
(−1.75 to 1.38, p=0.82). Furthermore, the 36-month
follow-up study did not ﬁnd any long-term effect of
DAISY on any of the other primary and secondary out-
comes (tables 2 and 3).
At baseline, the patients were at the very early stage of
dementia with a mean MMSE of 24.1 (SD 2.6). At the
36-month follow-up, there was a marked fall in MMSE
mean scores of 6–7 in both groups, accompanied by a
marked deterioration in the patients’ quality of life
(table 2). Additionally, the patients were well functioning
in their ADL and had very few behavioural problems at
baseline. At the 36-month follow-up, ADL had deterio-
rated markedly and behavioural symptoms had emerged
(table 2). Participants in both group had few depressive
symptoms at baseline and minimal changes in their
mean Cornell Depression Scale scores at the 36-month
follow-up as compared to the baseline (table 2 and 3).
The study found no effect of DAISY on caregivers’ self-
rated quality of life and depressive symptoms at the
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36-month follow-ups. The caregivers were characterised
by a lack of depressive symptoms and a high self-rated
quality of life at the baseline (table 1). At the 36-month
follow-up, their depressive symptoms and self-rated
quality of life had changed minimally from baseline
(tables 2 and 3).
DISCUSSION
This study did not ﬁnd any long-term effect of an inten-
sive psychosocial intervention (DAISY) on patients and
caregivers beyond the effect of structured follow-up
support.
To our knowledge, this study is the largest randomised
controlled trial of early psychosocial intervention for
patients with mild AD and their caregivers to date, with
a long follow-up of 3 years. It is a study of solid
methodology, strictly adhering to CONSORT recommen-
dations. A priori sample size calculation was carried out.
The measures for primary and secondary outcomes are
reliable scales, which are commonly used in routine clin-
ical practice and in intervention studies across cul-
tures.26 27 Proper randomisation, allocation
concealment, rater-blinded evaluation of outcomes and
adjustment for multiple testing were rigorously carried
out to reduce biases that could lead to type I errors.11
The multicomponent semitailored intervention pro-
gramme was intensive in both content and duration, tar-
geted multiple needs, tended to the individual needs
and simultaneously involved caregivers and patients;
thus, having the characteristics that deﬁned successful
intervention programmes documented in the litera-
ture.2 5 7 Since ours was one of the ﬁrst studies to
examine the effect of support and counselling
Figure 1 Trial flow for Danish
Alzheimer Intervention Study.
(1) Patients and caregivers.
(2) Full compliance is defined as
participation from both the
caregiver and the patient in at
least three courses and three
counselling sessions each.
(3) In the analysis accounting for
dropouts, information from all
participating dyads were
incorporated.
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Table 1 Baseline characteristics of patients with Alzheimer’s disease and their caregivers who participated in the Danish
Alzheimer Intervention Study (DAISY)
Intervention (n=163) Control (n=167)
Patients’ characteristics
Sex
Male 76 (46.6) 75 (44.9)
Female 87 (53.4) 92 (55.1)
Mean (SD) age (years) 76.5 (7.7) 75.9 (6.6)
Household status
Living alone 54 (33.1) 48 (28.7)
Living with others 109 (66.9) 119 (71.3)
Home
Rented 66 (40.5) 56 (33.5)
Owned 97 (59.5) 111 (66.5)
Education
None 60 (36.8) 57 (34.1)
<3 years 39 (23.9) 49 (29.3)
≥3 years 64 (39.3) 61 (36.5)
Charlson comorbidity index
No comorbidity 64 (39.3) 73 (43.7)
1 comorbidity 75 (46.0) 65 (38.9)
≥2 comorbidities 24 (14.7) 29 (17.4)
Diagnosis
Pure Alzheimer’s disease 112 (68.7) 127 (76.1)
Mixed Alzheimer’s disease and vascular dementia 44 (27.0) 38 (22.8)
Lewy body dementia 7 (4.3) 2 (1.2)
Caregiver’s characteristics
Sex
Male 54 (33.1) 56 (33.5)
Female 109 (66.9) 111 (66.5)
Mean (SD) age (years) 65.5 (12.7) 66.5 (12.7)
Relation
Spouse 104 (63.8) 111 (66.5)
Child or child in law 45(27.6) 41(24.5)
Other 14 (8.6) 15 (9.0)
Living with patient
Yes 101/162 (62.4) 112/166 (67.5)
No 61/162 (37.6) 54/166 (32.5)
Home
Rent 45 (27.6) 45 (26.9)
Own 118 (72.4) 122 (73.1)
Education
None 41 (25.2) 37/166 (22.3)
<3 years 46 (28.2) 63/166 (37.9)
≥3 years 76 (46.6) 66 /166 (39.8)
Outcome measures at baseline
Primary patient outcomes
Mean (SD) MMSE 24.0 (2.5) 24.1 (2.7)
Mean (SD) Cornell Depression Scale 5.2 (4.8) 4.4 (4.0)
Mean (SD) proxy-rated EQ-VAS 62.1 (18.4) (n=162) 64.7 (20.4)
Primary caregiver outcome
Mean (SD) EQ-VAS 79.3 (16.3) (n=162) 81.4 (16.3)
Mean (SD) GDS 4.74 (5.2) (n=162) 4.71 (5.0)
Secondary patient outcome
Mean (SD) QoL-AD (proxy-rated) 33.0 (6.1) 34.7 (6.6)
Mean (SD) NPI-Q 3.9 (3.6) 3.9 (3.7)
Mean (SD) ADSC-ADL 61.2 (11.4) 61.8 (11.4)
Values are numbers (percentages) of participants unless stated otherwise.
ADSC-ADL, Alzheimer’s Disease Cooperative Study Activities of Daily Living Scale; EQ-VAS, European Quality of Life Visual Analogue
Scale; GDS, Geriatric Depression Scale; MMSE, Mini-Mental State Examination; NPI-Q, Neuropsychiatric Inventory Questionnaire; QoL-AD,
Quality of Life Scale for Alzheimer’s Disease.
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programmes in patients with very mild dementia, no
previous consensus exists concerning gold standards for
assessing efﬁcacy. Therefore, multiple primary and sec-
ondary outcomes were exploratively chosen based on
the speciﬁc aims of the DAISY and on the outcomes
from similar intervention studies for patients with more
advanced dementia.1 Consequently, to avoid ﬁnding
spurious effects, a signiﬁcance level was set at p=0.0005,
which was subsequently criticised for being too conserva-
tive.12 All patients in this study had primary caregivers
who were very involved in caregiving, a situation that
cannot be generalised to all patients with dementia in
Denmark.
Although not statistically signiﬁcant for this adjusted p
value, DAISY did produce small positive effects on redu-
cing depressive symptoms and maintaining quality of life
for the patients at the 12-month follow-up.11 The effect
size of DAISY regarding Cornell depression score was –
1.58 (−2.79 to −0.37, p=0.0103) and regarding proxy-
rated QoL-AD was 2.14 (0.83 to 3.45; p=0.0013). The
disease-speciﬁc QoL-AD is probably more sensitive to
measure the effect of psychological interventions than
general EQ-VAS.27 At the 36-month follow-up, these posi-
tive effects were no longer present. Between 12 and
36 months of follow-up, there was signiﬁcant decline in
patients’ cognition, quality of life and ADL. During this
time period, there was no continuing intervention or
support. Initially, the study was intended to end at the
12-month follow-up. However, we received additional
funding to carry out follow-up at 36 months. The timing
and duration of DAISY could have missed a period of
signiﬁcant decline when intervention could have been
more beneﬁcial. Possibly, the positive trends observed at
the 12-month follow-up could have been maintained or
enhanced had the intervention continued for an add-
itional 2 years. Evidence from the very limited literature
seems to support the hypothesis that the positive effects
of psychosocial interventions could be lost without
continuous reinforcement. There are few randomised
controlled trials assessing the efﬁcacy of psychosocial
intervention that speciﬁcally targets community-dwelling
patients with dementia.6 10 Most trials had short
follow-up period, usually 3–6 months. One trial showed
that a 3-month programme of intensive physical exercise
for the patients combined with teaching caregivers strat-
egies to manage patients’ behavioural problems
improved the patients’ physical functioning and depres-
sive symptoms.28 At 24-month follow-up, the improve-
ment in physical functioning was still signiﬁcant, but the
improvement of depressive symptoms was no longer
present.28 In contrast, another trial with 8-year follow-up
reported delayed nursing home placement for patients
by providing a multicomponent interventions for the
caregivers and patients; the 10-day intervention pro-
gramme was followed by continuous support over the
telephone, weekly for the ﬁrst year and yearly thereafter
for the next 7 years.29
In our study, there are some possible explanations
for the non-signiﬁcant positive effects found at the
12-month follow-up concerning patients’ depressive
symptoms and quality of life and the disappearance of
these effects at the 36-month follow-up. First, it could be
a ﬂoor effect. Our patients had minimal depressive
symptoms and relatively high scores of QoL-AD at base-
line. A randomised controlled trial using support group
intervention for community-dwelling patients with mild
AD and their caregivers showed that patients who experi-
enced improvement in their depressive symptoms had
signiﬁcantly more depressive symptoms at baseline and a
higher level of distress.30 Second, there was no need
assessment at baseline. Probably, participants with more
symptoms and at greater need should have received the
full intensive intervention programme and regular
support follow-up was sufﬁcient for those who had
minimal symptoms and needs at baseline. Third, the
control group also received some intervention that is
Table 2 Outcome measures of the DAISY psychosocial interventions based on completed response at 36-month follow-up
Observed scores Changes from baseline
Intervention Control Intervention Control
Primary patient outcomes
MMSE 17.8 (6.7) (n=84) 17.9 (7.1) (n=94) −6.21 (6.17) (n=84) −6.35 (6.26) (n=94)
Cornell Depression Scale 5.57 (4.78) (n=93) 5.17 (4.19) (n=101) 1.29 (4.94) (n=93) 0.74 (4.45) (n=101)
Proxy-rated EQ-VAS 50.7 (20.3) (n=95) 52.3 (21.0) (n=102) −12.88 (20.3) (n=95) −12.46 (19.0) (n=102)
Primary caregiver outcomes
EQ-VAS 79.4 (16.1) (n=94) 79.0 (18.0) (n=103) −0.79 (16.5) (n=94) −1.49 (16.5) (n=103)
GDS 5.26 (5.43) (n=94) 4.51 (5.26) (n=103) 0.81 (4.83) (n=94) 0.14 (4.52) (n=103)
Secondary patient outcomes
QoL-AD (proxy-rated) 30.5 (5.1) (n=96) 32.1 (6.2) (n=103) −2.89 (4.89) (n=96) −2.84 (2.00) (n=103)
NPI-Q 5.21 (4.43) (n=96) 5.05 (4.80) (n=104) 1.57 (4.43) (n=96) 1.20 (4.68) (n=104)
ADSC-ADL 35.3 (19.4) (n=96) 41.3 (20.8) (n=104) −26.7 (16.6) (n=96) −22.3 (19.6) (n=104)
Values are means (SD) unless stated otherwise.
ADSC-ADL, Alzheimer’s Disease Cooperative Study Activities of Daily Living Scale; DAISY, Danish Alzheimer Intervention Study; EQ-VAS,
European Quality of Life Visual Analogue Scale; GDS, Geriatric Depression Scale; MMSE, Mini Mental State Examination; NPI-Q,
Neuropsychiatric Inventory Questionnaire; QoL-AD, Quality of Life Scale for Alzheimer’s Disease.
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much better than the usual practice in Denmark.31 They
had regular follow-ups when they could speak about
emerging psychosocial and health problems, receive
information about available resources, and get referred
to relevant health professionals if needed. It is note-
worthy that despite the marked decline in patients’
global cognitive function, quality of life and ADL
between 12 and 36 months of follow-ups, participants in
both groups had minimal changes in mean Cornell
Depression Scale scores as compared to the baseline.
This could be an indication that the regular follow-ups
offered in this study were sufﬁcient enough to produce
a long-term effect in preventing the conversion into clin-
ical depression for the patients. Fourth, as aforemen-
tioned, the intervention should probably continue
longitudinally following the clinical progression in these
patients to show long-term positive effects. The study did
not ﬁnd any long-term effect on DAISY on the caregiver
outcomes. Previous studies have shown positive
responses to interventions from caregivers with high
levels of depression and anxiety at baseline.10 For this
mostly asymptomatic group of caregivers in our study,
perhaps follow-up at regular intervals provided enough
information and support to prevent the emergence of
depressive symptoms and maintain good life quality.
It is not known why patients in the intervention group
had higher mortality than those in the control group.
This increased mortality was unlikely to be caused by the
intervention, as the nature of the intervention pro-
gramme did not subject the patients to any health risk.
Using the data from Statistics Denmark (http://www.dst.
dk), the incidence of death for the age-matched general
population over the same time period was found to be
similar to that of the DAISY group. The control group,
however, had lower incidence of death compared with
the general population. At baseline, the quality of life of
the patients in the intervention group was rated as
poorer than that of the control group, both by the
patients themselves and by their caregivers (table 1).
Although not statistically signiﬁcant, there were small
socioeconomic and clinical differences that could be
responsible for the higher mortality rate in the interven-
tion groups. More patients in the intervention group
lived alone (4% difference), rented their house (7% dif-
ference), had more comorbidities (4.4% difference)
and were diagnosed with mixed AD and vascular demen-
tia (4.2% difference, table 1). Whether these differences
could contribute to the higher mortality in the interven-
tion group is uncertain. It is known that older people
living alone have higher mortality than those living with
others.32 Currently, there is insufﬁcient evidence in the
literature concerning the effect of psychosocial interven-
tion on patient mortality, as studies looking at this effect
are scarce.5 33
The same patient characteristics in the DAISY group
stated above could also explain the lack of effect con-
cerning nursing home placement.34 Additionally, con-
tinuous intervention and follow-up between 12 and
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36 months could have been needed to produce a posi-
tive long-term effect on nursing home placement.
Randomised controlled trials that reported positive long-
term effect of psychosocial intervention on patients’
nursing home placement provided continuous support
and counselling over the phone for 8–9 years.29 35 In
contrast, intervention lasting 2 years but without con-
tinuous follow-up and support showed no long-term
effect on nursing home placement.33
Although this study found no long-term effect of
DAISY, a qualitative study linked to this randomised con-
trolled trial showed that 80% of patients and 94% of
caregivers in the intervention group found the interven-
tion overall beneﬁcial. Patients felt that their self-esteem
was improved and they could better manage their daily
life and social relations. Caregivers felt that they were
more conﬁdent and competent to cope with the chal-
lenges of caring for relatives with AD. After the interven-
tion, patients and caregivers looked for support groups
to join permanently and caregivers sought continued
counselling.36 In contrast to randomised clinical trials
about pharmacological interventions, we did not carry
out DAISY to justify the reason for providing psycho-
social intervention for patients with dementia and their
caregivers, whose need for information, counselling and
support cannot be denied. What we can conclude from
this study is that since we could not show positive effects
in the quantitative analyses, we should not offer psycho-
social intervention indiscriminately to all patients with
very mild dementia and their caregivers, but we should
probably assess their needs and offer intervention only
to those who need it. Regular follow-up is therefore
important to identify the arising needs that require
intervention. Probably, the type, dose and intensity, and
duration of early intervention should be more tailored
to match the needs of patients and their caregivers at
baseline to maximise beneﬁt, economise resources and
avoid unnecessary intervention burden. The interven-
tion programme should perhaps be designed in such a
way that patients and caregivers with greater needs at
baseline receive more intensive interventions that cater
to their speciﬁc needs, those with lesser needs receive a
basic intervention programme of lower intensity and
those with minimal or no needs receive no intervention
at all. To obtain long-term effect, early intervention
should probably have a longitudinal and ﬂuid course
that follows the disease progression, being continuously
modiﬁed according to the needs that arise. These are
the questions to be answered in future studies.
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